1 June 2026 - GSK Korea said Monday that its myelofibrosis treatment Omjjara (momelotinib hydrochloride hydrate) has been granted reimbursement coverage under Korea's national health insurance program for patients with intermediate-2 or higher-risk myelofibrosis and anaemia, defined as haemoglobin levels below 10.0 g/dL.

The reimbursement applies to adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis classified as International Prognostic Scoring System intermediate-2 or high risk.

Read Korea Biomedical Review article